BEYFORTUS is a long-acting monoclonal antibody approved for the prevention of RSV lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season, and ...

BEYFORTUS administration can be timed to coincide with the RSV season. BEYFORTUS has been approved for use in the US, the European Union, China, Japan, and many other countries around the world.

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

Beyfortus made $1.8 billion in sales last year, even though supplies were held back by now-resolved production constraints.

Sanofi Q2 sales rose 10.1% at constant currency, led by Dupixent and ALTUVIIIO. EPS missed estimates; 2025 sales guidance was ...

Investing.com -- Sanofi (EPA: SASY) shares fell more than 2% on Thursday after the pharmaceutical and healthcare company ...

The Beyfortus® distribution agreement builds upon Dr. Reddy's successful vaccine partnership with Sanofi established in 2024 as part of its strategy of“expanding innovation and building for ...

AstraZeneca ’s AZN second-quarter 2025 core earnings of $1.09 per American depositary share (ADS) came in line with the Zacks ...

The study found the program was more than 85% effective in reducing infant hospitalizations, emergency-room consultations and ...

Along with Beyfortus (nirsevimab), it is also a potential rival to Pfizer's RSV vaccine Abrysvo, which can be given to women during pregnancy to protect their babies for the first six months after ...